AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Spire Global, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) � Form 4 filing, 21 Jul 2025. Sr. VP, General Counsel & Secretary Meredith W. Cook reported a tax-related share withholding transaction on 18 Jul 2025.

  • Transaction type: Code F (shares withheld to satisfy taxes on vested restricted stock).
  • Securities affected: 2,071 common shares at an implied price of $66.30, total â‰� $0.14 million.
  • Post-transaction holding: Cook now directly owns 76,874 common shares.
  • Derivative positions: No derivative transactions reported; prior option/RSU holdings unchanged.

The filing reflects routine tax withholding rather than an open-market sale. Cook retains >97% of her pre-vesting equity stake, signalling continued alignment with shareholders. No impact on the company’s operations, earnings outlook or governance structure was disclosed.

ANI Pharmaceuticals (ANIP) � Deposito Form 4, 21 luglio 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha segnalato una transazione di ritenuta azionaria a fini fiscali il 18 luglio 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte su azioni ristrette maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di $66,30, per un totale di circa $0,14 milioni.
  • Posizione dopo la transazione: Cook detiene ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivative: Nessuna transazione derivata segnalata; le precedenti posizioni in opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine e non una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-maturazione, indicando un continuo allineamento con gli azionisti. Non sono stati comunicati impatti sulle operazioni dell’azienda, sulle previsioni di utili o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) � Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones relacionada con impuestos el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2,071 acciones comunes a un precio implícito de $66.30, total aproximado de $0.14 millones.
  • Posición tras la transacción: Cook posee ahora directamente 76,874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las posiciones previas en opciones/RSU permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria previa a la adquisición, lo que indica un alineamiento continuo con los accionistas. No se revelaron impactos en las operaciones de la compañía, perspectivas de ganancias o estructura de gobernanza.

ANI Pharmaceuticals (ANIP) â€� 2025ë…� 7ì›� 21ì� Form 4 제출. ìˆ˜ì„ ë¶€ì‚¬ìž¥ ê²� 법률 고문 ë°� 비서ì� Meredith W. Cookê°€ 2025ë…� 7ì›� 18ì� 세금 ê´€ë � ì£¼ì‹ ì›ì²œì§•수 거래ë¥� 보고했습니다.

  • 거래 유형: 코드 F (확정 제한 주ì‹ì—� 대í•� 세금 ë‚©ë¶€ë¥� 위한 ì£¼ì‹ ì›ì²œì§•수).
  • ì˜í–¥ì� ë°›ì€ ì¦ê¶Œ: 암시ì � ê°€ê²� $66.30ì—� 2,071 보통ì£�, ì´� ì•� $0.14백만.
  • 거래 í›� 보유 주ì‹: CookëŠ� 현재 ì§ì ‘ 76,874 보통주를 보유하고 있습니다.
  • 파ìƒìƒí’ˆ í¬ì§€ì…�: 파ìƒìƒí’ˆ 거래 ë³´ê³  ì—†ìŒ; ì´ì „ 옵션/RSU 보유ëŠ� ë³€ë� ì—†ìŒ.

ì´ë²ˆ ì œì¶œì€ ê³µê°œì‹œìž¥ 매ë„ê°€ 아닌 ì¼ìƒì ì¸ 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�. CookëŠ� 행사 ì´ì „ ì§€ë¶„ì˜ 97% ì´ìƒì� 보유하여 주주와ì� ì§€ì†ì ì� ì´í•´ê´€ê³� ì¼ì¹˜ë¥� 나타냅니ë‹�. 회사 ìš´ì˜, ìˆ˜ìµ ì „ë§ ë˜ëŠ” 거버넌스 구조ì—� 미치ëŠ� ì˜í–¥ì€ 공개ë˜ì§€ 않았습니ë‹�.

ANI Pharmaceuticals (ANIP) � Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à la fiscalité le 18 juillet 2025.

  • Type d’opération : Code F (actions retenues pour couvrir les impôts sur les actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit un total d’environ 0,14 million de dollars.
  • Détention après opération : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions dérivatives : Aucune transaction dérivative signalée ; positions antérieures en options/RSU inchangées.

Le dépôt reflète une retenue fiscale de routine plutôt qu’une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, ce qui indique un alignement continu avec les actionnaires. Aucun impact sur les opérations de la société, les perspectives de bénéfices ou la structure de gouvernance n’a été communiqué.

ANI Pharmaceuticals (ANIP) � Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Secretary, meldete am 18. Juli 2025 eine steuerbedingte Aktienrückbehaltstransaktion.

  • Transaktionstyp: Code F (Aktien einbehalten zur Begleichung von Steuern auf erworbene Restricted Stocks).
  • Betroffene Wertpapiere: 2.071 Stammaktien zu einem impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach Transaktion: Cook besitzt nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; vorherige Optionen/RSU-Bestände unverändert.

Die Einreichung spiegelt eine routinemäßige Steuerabführung wider und keinen Verkauf am offenen Markt. Cook hält über 97 % ihres Anteils vor der Vesting-Periode, was auf eine fortgesetzte Ausrichtung mit den Aktionären hinweist. Es wurden keine Auswirkungen auf den Geschäftsbetrieb, die Gewinnprognose oder die Governance-Struktur bekannt gegeben.

Positive
  • Executive retains 76,874 shares, indicating continued equity exposure and alignment with shareholders.
Negative
  • 2,071 shares were disposed of (withheld for taxes), mildly increasing share float, though impact is immaterial.

Insights

TL;DR: Routine tax withholding; negligible market impact.

The Code F disposition simply covers payroll taxes on 4,820 vested RSUs. At � $137k, it is immaterial relative to ANIP’s average daily dollar volume and the executive’s remaining 76.9k-share stake. Because there was no discretionary sale, the signal value is neutral. Investors should not read this as a change in insider sentiment. Impact on float and EPS is de minimis.

ANI Pharmaceuticals (ANIP) � Deposito Form 4, 21 luglio 2025. Meredith W. Cook, Vicepresidente Senior, Consigliere Generale e Segretaria, ha segnalato una transazione di ritenuta azionaria a fini fiscali il 18 luglio 2025.

  • Tipo di transazione: Codice F (azioni trattenute per soddisfare le imposte su azioni ristrette maturate).
  • Azioni interessate: 2.071 azioni ordinarie a un prezzo implicito di $66,30, per un totale di circa $0,14 milioni.
  • Posizione dopo la transazione: Cook detiene ora direttamente 76.874 azioni ordinarie.
  • Posizioni derivative: Nessuna transazione derivata segnalata; le precedenti posizioni in opzioni/RSU rimangono invariate.

Il deposito riflette una ritenuta fiscale di routine e non una vendita sul mercato aperto. Cook mantiene oltre il 97% della sua partecipazione azionaria pre-maturazione, indicando un continuo allineamento con gli azionisti. Non sono stati comunicati impatti sulle operazioni dell’azienda, sulle previsioni di utili o sulla struttura di governance.

ANI Pharmaceuticals (ANIP) � Presentación Formulario 4, 21 de julio de 2025. Meredith W. Cook, Vicepresidenta Senior, Asesora General y Secretaria, reportó una transacción de retención de acciones relacionada con impuestos el 18 de julio de 2025.

  • Tipo de transacción: Código F (acciones retenidas para cubrir impuestos sobre acciones restringidas adquiridas).
  • Valores afectados: 2,071 acciones comunes a un precio implícito de $66.30, total aproximado de $0.14 millones.
  • Posición tras la transacción: Cook posee ahora directamente 76,874 acciones comunes.
  • Posiciones derivadas: No se reportaron transacciones derivadas; las posiciones previas en opciones/RSU permanecen sin cambios.

La presentación refleja una retención fiscal rutinaria y no una venta en el mercado abierto. Cook conserva más del 97% de su participación accionaria previa a la adquisición, lo que indica un alineamiento continuo con los accionistas. No se revelaron impactos en las operaciones de la compañía, perspectivas de ganancias o estructura de gobernanza.

ANI Pharmaceuticals (ANIP) â€� 2025ë…� 7ì›� 21ì� Form 4 제출. ìˆ˜ì„ ë¶€ì‚¬ìž¥ ê²� 법률 고문 ë°� 비서ì� Meredith W. Cookê°€ 2025ë…� 7ì›� 18ì� 세금 ê´€ë � ì£¼ì‹ ì›ì²œì§•수 거래ë¥� 보고했습니다.

  • 거래 유형: 코드 F (확정 제한 주ì‹ì—� 대í•� 세금 ë‚©ë¶€ë¥� 위한 ì£¼ì‹ ì›ì²œì§•수).
  • ì˜í–¥ì� ë°›ì€ ì¦ê¶Œ: 암시ì � ê°€ê²� $66.30ì—� 2,071 보통ì£�, ì´� ì•� $0.14백만.
  • 거래 í›� 보유 주ì‹: CookëŠ� 현재 ì§ì ‘ 76,874 보통주를 보유하고 있습니다.
  • 파ìƒìƒí’ˆ í¬ì§€ì…�: 파ìƒìƒí’ˆ 거래 ë³´ê³  ì—†ìŒ; ì´ì „ 옵션/RSU 보유ëŠ� ë³€ë� ì—†ìŒ.

ì´ë²ˆ ì œì¶œì€ ê³µê°œì‹œìž¥ 매ë„ê°€ 아닌 ì¼ìƒì ì¸ 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•©ë‹ˆë‹�. CookëŠ� 행사 ì´ì „ ì§€ë¶„ì˜ 97% ì´ìƒì� 보유하여 주주와ì� ì§€ì†ì ì� ì´í•´ê´€ê³� ì¼ì¹˜ë¥� 나타냅니ë‹�. 회사 ìš´ì˜, ìˆ˜ìµ ì „ë§ ë˜ëŠ” 거버넌스 구조ì—� 미치ëŠ� ì˜í–¥ì€ 공개ë˜ì§€ 않았습니ë‹�.

ANI Pharmaceuticals (ANIP) � Dépôt du Formulaire 4, 21 juillet 2025. Meredith W. Cook, Vice-Présidente Senior, Conseillère Juridique Générale et Secrétaire, a déclaré une opération de retenue d’actions liée à la fiscalité le 18 juillet 2025.

  • Type d’opération : Code F (actions retenues pour couvrir les impôts sur les actions restreintes acquises).
  • Titres concernés : 2 071 actions ordinaires à un prix implicite de 66,30 $, soit un total d’environ 0,14 million de dollars.
  • Détention après opération : Cook détient désormais directement 76 874 actions ordinaires.
  • Positions dérivatives : Aucune transaction dérivative signalée ; positions antérieures en options/RSU inchangées.

Le dépôt reflète une retenue fiscale de routine plutôt qu’une vente sur le marché ouvert. Cook conserve plus de 97 % de sa participation avant acquisition, ce qui indique un alignement continu avec les actionnaires. Aucun impact sur les opérations de la société, les perspectives de bénéfices ou la structure de gouvernance n’a été communiqué.

ANI Pharmaceuticals (ANIP) � Form 4 Einreichung, 21. Juli 2025. Meredith W. Cook, Senior VP, General Counsel & Secretary, meldete am 18. Juli 2025 eine steuerbedingte Aktienrückbehaltstransaktion.

  • Transaktionstyp: Code F (Aktien einbehalten zur Begleichung von Steuern auf erworbene Restricted Stocks).
  • Betroffene Wertpapiere: 2.071 Stammaktien zu einem impliziten Preis von 66,30 $, insgesamt ca. 0,14 Mio. $.
  • Bestand nach Transaktion: Cook besitzt nun direkt 76.874 Stammaktien.
  • Derivative Positionen: Keine derivativen Transaktionen gemeldet; vorherige Optionen/RSU-Bestände unverändert.

Die Einreichung spiegelt eine routinemäßige Steuerabführung wider und keinen Verkauf am offenen Markt. Cook hält über 97 % ihres Anteils vor der Vesting-Periode, was auf eine fortgesetzte Ausrichtung mit den Aktionären hinweist. Es wurden keine Auswirkungen auf den Geschäftsbetrieb, die Gewinnprognose oder die Governance-Struktur bekannt gegeben.

false000181601700018160172025-07-152025-07-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 15, 2025

SPIRE GLOBAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39493

85-1276957

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

8000 Towers Crescent Drive

Suite 1100

Vienna, Virginia

22182

(Address of principal executive offices)

(Zip code)

Registrant’s telephone number, including area code: (202) 301-5127

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 


 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Class A common stock, par value of $0.0001 per share

SPIR

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 


 

Item 4.01. Changes in Registrant’s Certifying Accountant.

 

On July 15, 2025, PricewaterhouseCoopers LLP (“PwC”) notified Spire Global, Inc. (the “Company”) of its resignation as the Company’s independent registered public accounting firm for the year-end audit for the fiscal year ending December 31, 2025. The resignation will be effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Quarterly Report”) with the Securities and Exchange Commissions (the “SEC”). The Company will file an amendment to this Current Report on Form 8-K no later than four business days of filing the Quarterly Report with the specific date of termination and an update to the disclosures required by Item 304(a) of Regulation S-K through that date.

 

The audit reports of PwC on the Company’s consolidated financial statements for the Company’s fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that each such report contained an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern.

 

During the Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through the date of this Current Report on Form 8-K, there were no disagreements (within the meaning of Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the subject matter of the disagreements in connection with PwC’s reports on the Company’s financial statements.

 

During the Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through the date of this Current Report on Form 8-K, the only “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K) were PwC’s communication to the Company of the material weakness in disclosure controls and procedures disclosed in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2024 (the “2024 Form 10-K/A”), and the material weaknesses in internal control over financial reporting disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2023 (the “2023 Form 10-K/A”), and the 2024 Form 10-K/A. Descriptions of the foregoing material weaknesses under the headings (i) “Management's Report on Internal Control over Financial Reporting” in Part II, Item 9A. “Controls and Procedures” in the 2023 Form 10-K/A and the 2024 Form 10-K/A, (ii) “Evaluation of Disclosure Controls and Procedures” in Part II, Item 9A. “Controls and Procedures” in the 2024 Form 10-K/A, and (iii) “Material Weaknesses in Internal Control over Financial Reporting” in Part II, Item 9A. “Controls and Procedures” in the 2023 Form 10-K are incorporated herein by reference.

 

The Audit Committee is in the process of conducting a request for proposal process to identify an independent registered public accounting firm to replace PwC. The Audit Committee discussed with PwC the reportable events described above, and the Company has authorized PwC to respond fully to the inquiries of the Company’s successor independent registered public accounting firm concerning these reportable events.

 

The Company has provided PwC with a copy of the disclosures made in this Current Report on Form 8-K prior to its filing with the SEC and requested that PwC furnish the Company with a letter addressed to the SEC stating whether PwC agrees with the statements made herein. A copy of PwC’s letter is attached as Exhibit 16.1 to this Current Report on Form 8-K.

 

Item 8.01. Other Events.

 

Because of additional accounting activities required to finalize the Company’s condensed consolidated financial statements as of and for the three and six months ended June 30, 2025, including as a result of the closing of the sale of the Company’s maritime business to Kpler Holding SA, the Company does not currently expect to be able to file the Quarterly Report on or before the deadline for such filing or within the extension period of five calendar days permitted under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

Cautionary Note Regarding Forward-Looking Statements

 


 

This filing contains forward-looking statements, including information about the Company’s planned search for a new independent registered public accounting firm and the anticipated delay in filing the Quarterly Report, within the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of the Company to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are included in documents the Company files with the SEC, including but not limited to, the 2024 Form 10-K/A, as well as subsequent reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this filing are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company expressly disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibits

Description

16.1

Letter from PricewaterhouseCoopers LLP, dated July 21, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SPIRE GLOBAL, INC.

Date:

July 21, 2025

By:

  /s/ Theresa Condor

Name:

Title:

Theresa Condor

President and Chief Executive Officer

 


FAQ

What did ANIP insider Meredith Cook report in the Form 4 filed 21-Jul-2025?

She disclosed 2,071 shares of ANIP common stock were withheld on 18-Jul-2025 to pay taxes on vested RSUs.

How many ANIP shares does Meredith Cook now own?

After the transaction, she directly holds 76,874 common shares.

Was this an open-market sale of ANIP stock?

No. The Code F designation indicates shares were withheld by the company for tax purposes, not sold on the market.

Does the Form 4 affect ANIP’s earnings or guidance?

No operational or financial guidance was provided; the filing only details insider share movements.

Is the 2,071-share disposition material to ANIP shareholders?

At � $137k and <0.01% of shares outstanding, the impact is not material to valuation or float.
Spire Global Inc

NYSE:SPIR

SPIR Rankings

SPIR Latest News

SPIR Latest SEC Filings

SPIR Stock Data

349.30M
28.45M
6.07%
29.1%
10.89%
Specialty Business Services
Communications Services, Nec
United States
VIENNA